From GlobeNewswire:

Immix Biopharma, Inc. has announced the pricing of its public offering of 5,535,055 shares of common stock at a price of $2.71 per share, with a 30-day option to purchase an additional 783,970 shares. The total gross proceeds are expected to be approximately $15 million which will be used for NXC-201 clinical trials, working capital, and general corporate purposes. The offering is being made pursuant to an effective “shelf” registration statement and will be closed on February 8, 2024, subject to customary conditions. Titan Partners Group, a division of American Capital Partners, is the sole book-running manager for the offering. This press release does not constitute an offer but invites interested parties to obtain further information from the SEC.



Read more: Immix Biopharma Announces Pricing of $15 Million Public